视力相对较好时检测新生血管性年龄相关性黄斑变性的潜在重要性
该文讨论抗血管内皮生长因子治疗时代新生血管性年龄相关性黄斑变性(nvAMD)的检测时机问题。文中指出治疗开始时视力越好,随后至少2年视力维持较好的可能性越高;而患者从中期AMD进展为nvAMD至确诊期间平均可能丢失3至5行视力,确诊前nvAMD可能已存在6至12个月。作者认为在发生实质视力丧失前识别nvAMD可能减少视力丢失并改善视力结局。
要点
- 治疗开始时视力越好,随后至少2年视力较好的可能性越高。
- 患者从中期AMD进展为nvAMD至确诊期间平均可能丢失3至5行视力,甚至更多。
- 患者确诊并开始治疗前可能已患nvAMD 6至12个月。
核心结论
- 在发生实质视力丧失前识别nvAMD的额外工具或其他努力可能减少抗血管内皮生长因子治疗所伴的视力丢失量,并有可能大幅改善视力结局。
研究设计与样本
- 本文为PubMed收录的JAMA Ophthalmol文章,原文未报告具体研究设计。
主要发现
- 多项研究显示,治疗开始时视力越好,随后至少2年视力较好的可能性越高。
- 中期AMD患者的数据与nvAMD确诊时视力数据提示,患者从中期AMD进展为nvAMD至确诊期间平均可能丢失3至5行视力,甚至更多。
- 患者确诊并开始治疗前可能已患nvAMD 6至12个月。
- 当前nvAMD管理主要致力于优化抗血管内皮生长因子治疗,其改善视力结局的幅度可能以字母数计。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The advent of anti-vascular endothelial growth factor treatment has changed the prognosis for patients with neovascular age-related macular degeneration (nvAMD). The ability to stabilize or improve vision with these treatments is a major step in enabling patients to continue to function at the highest possible level. Many studies have demonstrated that the better the visual acuity (VA) is at the time of treatment initiation, the higher the likelihood that VA will be better during at least the following 2 years; as such, detection of nvAMD when VA is relatively good is important. Data on the VA of patients with intermediate AMD and VA at the time of nvAMD diagnosis suggest that patients are typically losing an average of 3 to 5 lines of vision and possibly more between the time that intermediate AMD progresses to nvAMD and the diagnosis of nvAMD is made. The average patient may have nvAMD for 6 to 12 months before diagnosis and treatment initiation. Current efforts in management of nvAMD are primarily aimed at optimizing anti-vascular endothelial growth factor treatments that have the potential to improve VA outcomes by a magnitude of letters. Additional tools or other efforts to identify patients with nvAMD before substantial vision loss has occurred may reduce the amount of visual loss sustained with anti-vascular endothelial growth factor therapy, and have the potential to improve VA outcomes substantially.
引用
- Ho AC, Albini TA, Brown DM, et al. The Potential Importance of Detection of Neovascular Age-Related Macular Degeneration When Visual Acuity Is Relatively Good. JAMA Ophthalmol. 2017. PMID: 28114653. doi:10.1001/jamaophthalmol.2016.5314
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。